A Changing Landscape of Advanced Prostate Cancer: Understanding Mechanisms of Resistance to Potent Hormonal Therapies
Technical Report,30 Sep 2014,29 Sep 2015
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY New York United States
Pagination or Media Count:
Transition to a neuroendocrine prostate cancer NEPC phenotype has emerged as an important mechanism of treatment resistance to androgen receptor AR therapies for patients with metastatic prostate cancer. During the course of this Award, I have performed extensive, first in-field molecular characterization of metastatic tumor biopsies from 81 patients with castration resistant adenocarcinoma and neuroendocrine prostate cancer Beltran et al, Nature Medicine, in press. Whole exome, transcriptome, and CpG DNA methylation integrative analyses point to key drivers of NEPC including loss of RB1 and TP53 and primarily epigenetic changes.